Caixin
Jan 09, 2019 07:31 PM
BUSINESS & TECH

Samsung Biotech Unit Partners With Chinese Firm for Biosimilar Push

Biologics are medicines made from living cells that must be stored under special conditions, and biosimilars are nearly identical copies of biologics already approved by a regulator.Photo: VCG
Biologics are medicines made from living cells that must be stored under special conditions, and biosimilars are nearly identical copies of biologics already approved by a regulator.Photo: VCG

A biopharmaceutical research unit of South Korea’s Samsung Group has partnered with a Chinese drugmaker to tap the burgeoning local biosimilar sector.

Samsung Bioepis Co. Ltd. on Monday announced it has signed a licensing agreement with Chinese biotech company 3SBio Inc. to develop and commercialize biosimilar medicines in China, the company’s first foray into the market.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
Copyright © 2017 Caixin Global Limited. All Rights Reserved.